Since G12C mutant lung cancer is an immunologically hot tumor it was evident to start combinations with PD1/PDL1 inhibitors: in case of sotorasib the combination partner is AKG404 (a PD1 inhibitor) in case of adagrasib the partner is Pembrolizumab (also a PD1 inhibitor). This evidence concerns the gene CD274 and lung carcinoma.